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ment. Thus, we concluded that UDCA administration im-Liver disease is increasingly recognized as a major
proves clinical and biochemical parameters in CF pa-cause of morbidity in cystic fibrosis (CF). Preliminary
tients with liver disease. Taurine supplementation maydata suggest that ursodeoxycholic acid (UDCA) may be
be indicated in patients with severe pancreatic insuffi-beneficial for treatment of this manifestation. We per-
ciency and poor nutritional status. (HEPATOLOGYformed a double-blind, multicenter trial in these pa-
1996;23:1484-1490.)tients to establish efficacy and safety of UDCA in terms
of the improvement of clinical and nutritional indicators
besides standard liver function tests. We also intended It has been speculated that chronic liver disease de-
to establish whether taurine supplementation has a ben- velops in patients with cystic fibrosis (CF) as a conse-
eficial effect in patients receiving UDCA. From June to quence of the plugging of intrahepatic bile ducts withDecember 1990, we enrolled in 12 centers 55 CF patients inspissated bile.1-3 The lack of CF transmembrane reg-with liver disease (39 male subjects; median age, 13.8
ulator in the apical membrane of bile duct cells, re-years). They were randomly assigned to receive for 1
cently documented in CF,4 may lead to abnormalitiesyear one of the following treatments: UDCA (15 mg/kg
in biliary drainage, with chronic cholestasis and thebody weight daily) plus taurine (30 mg/kg body weight
daily), UDCA plus placebo, placebo plus taurine, or dou- development of multilobular biliary cirrhosis. Ac-
ble placebo. Clinical and laboratory evaluations were cording to data from the American CF registry in 1990,
performed every 3 months. After 1 year, deterioration of liver disease is increasingly recognized as a cause of
overall clinical conditions, as indicated by the Shwach- morbidity.5,6 This probably reflects an increased preva-
man-Kulczycki score (SKS), occurred in patients who re- lence of hepatobiliary complications because CF pa-
ceived placebo but not in those who received UDCA (P tients live longer.5,6 A negative prognostic impact of .025). Patients treated with UDCA also showed an im- liver disease is thus to be expected in CF, as also sug-provement ing-glutamyl transpeptidase (GGT) (P .004)
gested by the recent identification of hepatomegaly asand 5*-nucleotidase (P .006) levels. Treatment with tau-
an independent risk factor for early death in affectedrine was followed by a significant increase in serum pre-
patients.7albumin levels (P  .053), a trend toward a reduction
in fat malabsorption, and no effect on the biochemical Over the last few years, we and others have found
profile. No severe side effects occurred with any treat- in open studies that treatment with ursodeoxycholic
acid (UDCA) can improve serum liver enzyme levels,
hepatic function, and nutritional status in patients
Abbreviations: CF, cystic fibrosis; UDCA, ursodeoxycholic acid; GGT, g- with CF and liver disease.8-17 UDCA is a hydrophilic
glutamyl transpeptidase; SKS, Shwachman-Kulczycki score. bile acid with choleretic properties.18 In patients with
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effect on the immune response in adult patients withFerrari (University of Florence), S. Scotta (University of Pavia), L. Minicucci
(University of Genoa), M. Candusso (University of Trieste), E. Valletta chronic cholestatic liver diseases has also been advo-
(Ospedale Civile Maggiore, Verona), R. Gagliardini (Ospedale dei Bambini cated.18 Confirmation of the beneficial effects of UDCA
G. Salesi, Ancona), F. Santamaria (University of Naples), and F. Battistini by placebo-controlled, double-blind studies was ob-
(Ospedale Bufalini, Cesena). tained on standard liver function tests as the only out-Presented in part at the 44th annual meeting of the American Association
come measure.11 Moreover, no study addressed the is-for the Study of Liver Diseases, Chicago, Illinois, November 1993, and pub-
lished in abstract form (HEPATOLOGY 1993;18:142A). sue of the need for taurine supplementation, which was
Address reprint requests to: Carla Colombo, M.D., Department of Pediat- recommended by some authors during concomitant
rics, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy. UDCA treatment in the assumption that chronic ad-Copyright q 1996 by the American Association for the Study of Liver
ministration of unconjugated UDCA may aggravate theDiseases.
0270-9139/96/2306-0027$3.00/0 degree of taurine deficiency in CF.8,12,19
1484
5p0e$$0038 05-30-96 07:28:01 hepa WBS: Hepatology
HEPATOLOGY Vol. 23, No. 6, 1996 COLOMBO ET AL. 1485
patients receiving UDCA (UDCA / T and UDCA / P) andWe designed a multicenter, double-blind, controlled
the remaining patients.trial in CF patients with associated liver disease to
Patients and/or parents were informed of the nature, pur-evaluate efficacy and safety of treatment with UDCA
pose, and requirements of the study before giving writtenon an extended spectrum of outcome measures, includ-
consent. The study was performed according to the principlesing nutritional and other clinically relevant parame- of the Helsinki declaration for research in human subjects.ters. In addition, we evaluated for the first time the The protocol was approved by the review institutional boards
effects of taurine supplementation, which was adminis- of the participating centers.
tered randomly in a double-blind fashion to patients Criteria for Evaluation. The primary objective of the study
taking UDCA or placebo. was to compare treatment groups with respect to changes in
clinically relevant and nutritional parameters (Shwachman-
Kulczycki score [SKS], fecal fat excretion, serum prealbuminPATIENTS AND METHODS
and lipid levels, prothrombin time, and urinary creatinine)
besides improvements in serum liver enzymes (serum trans-Patients and Study Design. Patients with a diagnosis of
CF and chronic liver disease with persistent alterations of aminases, GGTP, and 5*-nucleotidase). The SKS encom-
passes four categories: general activity, physical examina-serum liver enzymes were considered for admission into the
study at 12 centers in Italy. Diagnosis of CF had been pre- tion, nutrition, and chest radiographic findings.20,21
Clinical and standard laboratory evaluations were per-viously established on the basis of increased sweat chloride
concentrations and typical symptoms of pulmonary and pan- formed at the time of enrollment and every 3 months thereaf-
ter. Blood samples were obtained for determination of serumcreatic involvement. Chronic liver disease was defined on the
basis of: presence of hepatomegaly, confirmed by abnormal liver enzyme levels (alanine and aspartate aminotransfer-
ases, GGT, and alkaline phosphatase), total and conjugatedultrasonographic findings (increased liver size, nonhomoge-
neous echogenic pattern, and irregular surface), and the pres- bilirubin, cholinesterase, total and high-density lipoprotein
cholesterol, triglycerides, glucose, albumin, gamma globu-ence of abnormal liver biochemistries (serum transaminases,
g-glutamyl transpeptidase [GGT]) of at least 1 year’s dura- lins, immunoglobulins, prothrombin time, complete blood
counts, urea, and creatinine. Urine samples were obtainedtion. To ensure that an effect of UDCA on serum liver en-
zymes could be detected, presence of serum transaminase from 24-hour collection for determination of urinary creati-
nine excretion. These tests were performed in the clinicaland GGT levels exceeding 1.5 times the upper limit of normal
reference values on at least three determinations over the laboratory of each participating center by routine automated
techniques.year before entry into the study was also required for admis-
sion. Blood samples for determination of fasting serum bile acid
levels (conjugated cholic acid, chenodeoxycholic acid, andPatients were excluded if they were less than 3 years old,
if they had serum bilirubin 3 mg/dL, ascites, chronic viral UDCA, by solid-phase immunoenzymatic assays),22 serum
5*-nucleotidase (by enzymatic method), and prealbumin con-hepatitis, concomitant severe pulmonary disease, previous
episodes of variceal bleeding or encephalopathy, or portosys- centrations (by radial immunodiffusion) were obtained at
baseline and after 6 and 12 months of treatment. Their deter-temic shunting. Patients who had been treated with cortico-
steroids or other immunosuppressant agents in the previous mination was performed centrally in the same laboratory, in
the interest of standardization and double-blind design.6 months, as well as those previously included in other clini-
cal studies on UDCA, were also excluded. The SKS, abdominal ultrasound scanning, upper digestive
endoscopy (to be performed only in patients with splenomeg-Diagnosis of multilobular biliary cirrhosis was based on
histological criteria when recent liver biopsy specimens were aly and/or suspected portal hypertension), and fecal fat excre-
tion23 were evaluated at baseline and at the end of the study.available (five cases). The remaining patients were consid-
ered as having cirrhosis if one of the following indicators of Compliance to treatment was assessed by counting the cap-
sules returned to the clinic by the patient.portal hypertension were present: enlarged portal vein in the
absence of respiratory variation on ultrasound and platelet Analysis of Data. Serum liver enzyme values were stan-
dardized according to reference values for each laboratorycount 100 1 109/L; or esophageal varices at endoscopy.
Patients who fulfilled the criteria for enrollment were ran- and expressed as multiples of the upper limit of reference
values. Height and weight were expressed as z scores.domly assigned by a centrally computer-generated list to re-
ceive, on a weight basis, either UDCA or placebo at the daily Changes in SKS, height, weight, fecal fat excretion, and in
serum bile acid levels were expressed as differences betweendose of one to three 300-mg capsules for 1 year. Taurine or
a second placebo at the dose of one to three 500-mg capsules values at the last determination and those at baseline.
Changes over time in the remaining laboratory variablesdaily were randomly added double-blind to patients in either
group. Accordingly, patients received one of the following four were expressed as percentage difference.
ANOVA for factorial designs was used for estimation oftreatment combinations: UDCA plus taurine (UDCA / T);
UDCA plus placebo (UDCA / P); placebo plus taurine (P the effects of UDCA, of taurine, and of their interaction.24
Bartlett’s test was used for testing of homogeneity of vari-/ T); double placebo (P / P).
The sample size determination was based on the results ances. When nonhomogeneity of variances or departures from
normality were detected, data were analyzed using a loga-of a dose-response study of the effects of UDCA administra-
tion to CF patients with liver disease.16 In those patients, an rithmic transformation or the rank transformation ap-
proach.25 According to the latter method, the usual ANOVAimprovement in GGT levels corresponding to approximately
0.90 standard deviations had been achieved during daily ad- is applied to the ranks of the data instead of to the data
themselves. The association between changes in serum liverministration of 15 to 20 mg/kg body weight of UDCA. Assum-
ing no improvement in the two placebo groups (P / T and P enzyme levels and UDCA dosage, expressed on a weight ba-
sis, was studied by multiple-regression analysis. In this anal-/ P), we calculated that an overall sample size of 54 patients
would yield a probability of a type II error of 0.90, at the 5% ysis, the final values of serum liver enzymes were included
as the independent variable, the logarithm of the dose, andlevel of significance, in detecting such a difference between
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TABLE 1. Characteristics of Patients
UDCA Placebo
With Taurine Without Taurine With Taurine Without Taurine
(n  15) (n  15) (n  12) (n  13)
Mean age (yr) 14.2 { 4.2 11.3 { 3.6 14.8 { 3.7 12.8 { 3.8
Male subjects (%) 73 60 83 69
Height (z score) 00.65 { 0.72 00.75 { 1.00 00.93 { 0.86 00.85 { 1.32
Weight (z score) 01.03 { 0.66 00.83 { 0.91 00.80 { 0.99 00.65 { 1.93
With multilobular cirrhosis (%) 8 8 6 6
With esophageal varices (%) 4 1 0 0
NOTE. Plus-minus values are means { SD.
baseline serum liver enzyme values as independent vari- date for liver transplantation, which was performed
ables. successfully. All remaining subjects took more than
The total period of observation was used in the analysis of 80% of the prescribed dose, as assessed from the count
data for each patient, according to the ‘‘intention-to-treat’’ of unused capsules at each visit.
principle. No severe side effects were reported. Four patients,All the analyses were two-sided, and .05 was the level of
two in the UDCA / P group and two in the P / Pstatistical significance.
group, transiently complained of diarrhea and/or mild
and transient abdominal pain. One patient in theRESULTS
UDCA / P group experienced an episode of fever and
From June 1 to December 31, 1990, 55 patients (39 abdominal pain. None of these patients required any
male subjects) with a median age of 13.8 years (range, specific treatment or any modifications of the treat-4 to 22 years) were enrolled in 12 Italian centers. On ment schedule.the whole, 214 patients had been considered for admis- Efficacy of Treatments. One patient developed jaun-sion. Of the 159 of these patients who could not be dice and deterioration of liver function after 7 monthsenrolled, 55% had to be excluded for nonconformity to of treatment with UDCA and placebo. As indicatedbiochemical criteria for admission, 13% for previous above, she was withdrawn from the study and shortlyoccurrence of major complications of cirrhosis, 9% for after she underwent successful transplantation. An-severe pulmonary involvement, and 23% for other rea- other patient experienced an episode of melena aftersons, mainly for lack of consensus or previous inclusion 4 months of treatment with UDCA and taurine, butin other clinical trials. CF had been diagnosed at a treatment was not interrupted. Both patients had ad-median age of 1 year (range, 1 month to 13 years), and
vanced liver disease on entry into the study. No patientliver disease had been diagnosed at a median age of 9
developed ascites.years (range, 2 months to 18 years). All but 2 patients
During the study period, changes of the SKS andhad pancreatic insufficiency, which was partially cor-
of serum levels of GGT and 5*-nucleotidase differedrected by enzymatic therapy.
significantly in the two groups that were treated withFifteen patients were assigned to the UDCA / T
UDCA compared with the two other groups (Table 2).group, 15 to the UDCA / P group, 12 to the P / T
Among the components of the SKS, the score relativegroup, and 13 to the P/ P group. The main characteris-
to clinical conditions significantly worsened in the pa-tics of patients at the time of entry into the study are
tients who did not receive UDCA compared with pa-shown in Tables 1 and 2. By chance, all 5 patients
tients who did receive it (P  .020).with esophageal varices and 7 out of 8 patients with
Substantial improvements also occurred for aspar-abnormal serum bilirubin levels at entry had been as-
tate transaminase and alanine transaminase in thesigned to receive UDCA.
two UDCA groups, but the difference with patients notPatients in the two groups who received UDCA as-
receiving UDCA did not attain significance. No rela-sumed an average daily dose of 15 { 3 mg/kg body
tionship was found between changes in serum liverweight (range, 10 to 20 mg) of this bile acid, whereas
enzyme levels and UDCA dosage expressed on a weightthe average dose of taurine in the two taurine-supple-
basis. Serum prealbumin improved in patients who re-mented groups was 24 { 5 mg/kg b.w (range, 17 to 33
ceived taurine supplementation but not in the re-mg).
maining patients with a significant difference betweenWithdrawals and Side Effects. During the study pe-
taurine-supplemented patients and the other patients.riod, one patient in the UDCA / T group and another
A similar trend was observed for fecal fat excretion,in the P / P group left the study for personal choice.
although, in this case, that difference did not attainTwo other patients, both in the UDCA / P group, were
significance (Fig. 1). Serum cholesterol levels werewithdrawn for deterioration of clinical conditions, in-
within the normal range in basal conditions and did notvolving pulmonary disease in one case and liver disease
in the other. The latter patient then became a candi- change substantially during treatment. No significant
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TABLE 2. Initial Values of Biochemical and Nutritional Variables and Changes During Treatment
UDCA Placebo
With Taurine Without Taurine With Taurine Without Taurine
(n  15) (n  15) (n  12) (n  13)
SKS
Baseline 73 { 12 79 { 10 79 { 11 76 { 14
Change* 00.14 { 4.75¶ 0.00 { 2.65¶ 02.92 { 4.17 03.00 { 4.26
GGT†
Baseline 4.4 { 3.5 2.4 { 1.6 3.0 { 2.5 2.8 { 2.6
Change 031 { 28§ 026 { 35§ 31 { 68 015 { 33
5*-nucleotidase (IU/L) (n.v. 5)
Baseline 13.0 { 22.6 5.4 { 4.7 5.2 { 5.1 5.5 { 3.8
Change 021 { 34x 023 { 40x 26 { 43 42 { 126
AST†
Baseline 2.3 { 1.2 2.1 { 1.3 2.2 { 1.0 2.1 { 1.8
Change 029 { 49 024 { 25 013 { 32 010 { 40
ALT†
Baseline 3.2 { 2.2 2.2 { 1.0 2.8 { 1.7 3.6 { 4.3
Change 037 { 38 030 { 32 017 { 46 017 { 41
Prealbumin (mg/dL) (n.v. 20)
Baseline 18.0 { 3.4 19.1 { 6.4 18.4 { 7.4 18.0 { 4.6
Change 25 { 40# 03 { 14 36 { 69# 16 { 26
Daily fecal fat excretion (g) (n.v. 7)‡
Baseline 17 { 11 11 { 4 13 { 6 12 { 8
Change 04 { 12 3 { 16 04 { 4 03 { 10
NOTE. Values are means { SD.
Abbreviations: AST, aspartate transaminase; ALT, alanine transaminase; n.v., normal reference value.
* Changes are expressed as the difference between values at 12 months and basal values for the SKS, and for fecal fat excretion, and as
the percentage differences between values at 12 months and basal values for the remaining variables. Negative values indicate that a
decrease occurred during treatment.
† Data reported as multiples of the upper limit of normal reference values.
‡ Data for 7 and 9 patients who received UDCA with and without taurine, respectively, and for 8 and 6 patients who received placebo
with and without taurine, respectively.
§,x,¶ Significant difference between the two groups who received UDCA and the two other groups, P  .025, P  .006, and P  .004,
respectively.
# Significant difference between the two groups who received taurine and the two other groups (P  .053).
differences were found among patients concerning the variables in patients with CF complicated by liver dis-
other variables under study. Urinary creatinine in- ease. Only patients with persistent alterations of se-
creased in the patients in the UDCA / T group (30 rum liver enzyme levels were admitted into the study
{ 56%) and in those in the UDCA / P group (57 to base evaluation of the efficacy of UDCA on objective
{ 229%), whereas it remained unchanged in the two measurements. The design of the study also enabled
other groups. The difference between patients who re- us to establish whether taurine supplementation is
ceived UDCA and the remaining patients did not reach beneficial to patients on chronic UDCA treatment, in
the significance level. In the patients with more ad- view of the well-documented predisposition of CF pa-
vanced liver disease, i.e., those with varices and/or ele- tients to develop a deficiency of this amino acid.19
vated serum bilirubin levels, no significant changes in We chose not to include histological assessment
liver synthetic data (serum albumin, prealbumin, or among the study variables because the interpretation
prothrombin time) were observed. of serial biopsies is potentially misleading due to the
Baseline levels and changes during the study in se- heterogeneous distribution of hepatic lesions in CF,
rum UDCA and primary bile acids are reported in Ta- and performing repeat liver biopsies in our patients
ble 3. Data showed a high variability, and, with the was considered unethical.
exclusion of serum UDCA, no difference was found Much of the interest initially raised by UDCA in the
among treatment groups. treatment of chronic cholestatic diseases comes from
At baseline ultrasound examination, eight patients its ability to improve serum liver enzymes. An effect of
were found to have gallstones. One of these patients, the same magnitude as that reported in the litera-
belonging to the UDCA / T group, showed dissolution ture, i.e., an improvement of approximately 20 to
of a 3-mm stone at the end of the study. 40%,9,12,16,26-28 was consistently observed in our pa-
DISCUSSION tients, with no relationship to UDCA dose, expressed
on a weight basis. UDCA apparently did not influenceThe aim of the present study was to establish if
UDCA administration improves clinically relevant the liver inflammatory profile of our patients. Serum
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tories may have affected the results of the study. Al-
though a decrease in serum liver enzyme levels in CF
patients has been associated with concomitant im-
provement of bile secretory function,14 changes in bio-
chemical indicators do not necessarily reflect dimin-
ished liver damage or halting of disease progression.
Other clinically relevant outcome measures for liver
disease, such as liver transplantation or decompensa-
tion of cirrhosis, are hardly attainable by clinical stud-
ies on CF patients because these events are a late mani-
festation of the disease and occur infrequently.2,6
Thus far, only the effects on standard liver function
tests have been evaluated by a double-blind study,11
whereas the efficacy of UDCA has yet to be established
on other relevant end-points, including those of clinical
and nutritional interest. In patients with CF, it has
been reported that liver disease, regardless of its sever-
ity, may be associated with poor nutritional status, and
that patients with this complication may be predis-
posed to a higher mortality risk for causes other than
liver disease.2,6 To establish whether the beneficial ef-
fects of treatment also extended to overall clinical con-
ditions, we included the SKS20 as well as some indices
of nutritional status among the primary outcome mea-
sures. The SKS takes into account the severity of pul-
monary involvement, nutritional status, and general
patient’s conditions, and is widely used in the clinical
evaluation of CF patients. Its inclusion as an outcome
measure in clinical trials on CF patients has been re-
cently suggested.21 This score remained stable in the
patients who received UDCA and worsened in the re-
maining patients. We also observed a trend toward anFIG. 1. Changes in fecal fat excretion during the study. The dot-
increased urinary excretion of creatinine, which is con-ted lines represent the upper normal limits for fecal fat excretion.
Mean values are represented by boldface lines. sidered an index of muscle mass. A significant increase
in this parameter during UDCA administration was
reported by Cotting et al. in adult CF patients with
major nutritional problems.9,15 These findings suggestliver enzyme levels were standardized according to ref-
that UDCA administration may favorably affect clini-erence values for each laboratory, and no relationship
cal and nutritional status of CF patients with associ-was observed between their changes and patient cen-
ters. It seems unlikely that differences among labora- ated liver disease. This issue is still controversial be-
TABLE 3. Changes in Serum Conjugated Bile Acids
UDCA Placebo
With Taurine Without Taurine With Taurine Without Taurine
(n  10) (n  11) (n  10) (n  10)
UDCA
Baseline 1.1 { 1.9 0.5 { 1.6 0.4 { 0.6 1.0 { 2.6
Change* 3.4 { 6.8 5.8 { 6.4 00.1 { 0.5 0.5 { 1.9
CA (mmol/L)
Baseline 5.8 { 7.7 6.2 { 8.7 5.0 { 4.9 6.9 { 13.0
Change 01.6 { 6.4 00.7 { 4.0 01.1 { 3.1 04.1 { 9.6
CDCA (mmol/L)
Baseline 5.2 { 6.0 7.1 { 9.8 4.0 { 6.4 3.8 { 6.0
Change 01.6 { 5.3 01.7 { 3.4 01.0 { 1.7 00.4 { 7.2
NOTE. Data are expressed as means { SD.
Abbreviations: UDCA, ; CA, colic acid; CDCA, chenodeoxycholic acid.
* Changes are expressed as difference between values at 12 months and basal values. Negative values indicate that a decrease occurred
during treatment.
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